Check out the latest features and columns!

Pharmaceutical Executive October 2021

These five brands prove that pharma marketers can pull it together with compelling stories,  and meaningful patient impact, even during  a pandemic.

New Heights

October's Executive Profile features Imvax CEO John Furey

Leading Through Transition

Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.

Capitalizing on Collaboration: The Effort to Sustain Pandemic-Partnering Momentum

Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.

2021 Pharm Exec 50

Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.

Pharm Exec's 2021 Emerging Pharma Leaders

With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.

2021 in Focus: Pharm Exec’s Annual Industry Outlook

Articles

Adweek first published its list of Fastest-Growing Agencies in 2019.

Fingerpaint Named to Adweek’s Fastest-Growing Agencies List for Second Straight Year

Dr. Frank Douglas graduated with a B.S. in Engineering from Lehigh University in 1966. He went on to a Ph.D. in Physical Chemistry from Cornell University, with a thesis on chlorophyll-a. After a medical degree from Cornell University Medical School, he completed an internship and residency in internal medicine at Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health.

Following his fellowship, Douglas took a position as an assistant professor of medicine at the University of Chicago. He also began work at the pharma company Ciba-Geigy. In 1992, he became an executive vice president at Marion Merrell Dow, where he remained as it was acquired and changed names to Hoechst Marion Roussel, and later to Aventis. 

In 2005, Douglas left Aventis and took a position as a professor of the practice at Massachusetts Institute of Technology, where he was involved in founding the Center for Biomedical Innovation. After two years at MIT, he resigned over concerns about institutional racism. In 2009, Douglas moved to Akron, Ohio to serve as president and CEO of the Austen BioInnovation Institute. He left the institute at the beginning of 2015. 

Douglas published an autobiography in 2018, 

Defining Moments of a Free Man from a Black Stream.

How can large pharma improve D&I in its companies?

Addressing Systemic Racism in Biopharma

GM of Commercial Life Sciences, Komodo Health

Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.

Understanding the HCP: Patient-Level Data Proves Valuable 

Senior Vice President, Real-World Evidence & Access, Parexel

Vice President of Real-World Evidence Strategy, Parexel

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.

Industry Game Changer: RWE Impacts on Drug Development  

Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.

20th Annual Industry Audit: Year of the Pandemic 

Jill Wechsler is Pharm Exec's Washington Corespondent

New methods and policies necessitated by the global pandemic are slated to become permanent fixtures in FDA enforcement and regulatory programs.

Pandemic Alters FDA Inspections, Quality Oversight

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Unconventional collaborations between biopharma and tech are starting to take off.

Opposites Attract

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.

Defining the Chief Data Officer

Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.

While Q3 numbers look bleak, is improvement on the horizon?